JERRY T LIU
- ATTENDING PHYSICI | Radiation Oncology
Dr. Jerry Liu is a radiation oncologist with a clinical focus on personalized treatment of head and neck, hepatobiliary, gastrointestinal and lung malignancies, as well as metastatic disease. Working closely with his colleagues across various disciplines, Dr. Liu develops an individualized plan for each patient to deliver the most effective treatment, while minimizing toxicities by using innovative techniques such as Stereotactic Body Radiation Therapy (SBRT), Stereotactic Radiosurgery (SRS), Intensity Modulated Radiation Therapy (IMRT), and Image Guided Radiation Therapy (IGRT). Dr. Liu received his medical degree from Boston University School of Medicine and completed his residency in radiation oncology at The Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, where he served as chief resident and received the Roentgen Resident Research Award. His cancer research has resulted in publications in peer-reviewed journals and presentations at national and international scientific meetings. His primary research focus is identifying key predictors for outcomes and toxicities after treatment of head and neck cancer as well as other malignancies. He is primary and co-investigator of various head and neck cancer clinical trials. He is also working to optimize the use of SBRT in the treatment of liver and thoracic malignancies, as well as oligometastatic disease. While dedicated to caring for patients across all social, economic and cultural backgrounds, Dr. Liu is especially committed to promoting cancer awareness and optimizing comprehensive cancer care for the local Asian community. He works closely with the Asian Services Program at Mount Sinai Beth Israel to help patients navigate the healthcare system and is fluent in Mandarin Chinese.
MD, Boston University
Internship, Transitional, New York Hospital of Queens
Residency, Radiation Oncology, Icahn School of Medicine at Mount Sinai
Roentgen Resident/Fellow Research Award
Stock RG, Buckstein M, Liu JT, Stone NN. The relative importance of hormonal therapy and biological effective dose in optimizing prostate brachytherapy treatment outcomes. BJU international 2013 Jul; 112(2).
Ko EC, Liu JT, Stone NN, Stock RG. Association of early PSA failure time with increased distant metastasis and decreased survival in prostate brachytherapy patients. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2014 Feb; 110(2).
Liu JT, Kann BH, De B, Buckstein M, Bakst RL, Genden EM, Posner MR, Som PM, Gupta V. Prognostic value of radiographic extracapsular extension in locally advanced head and neck squamous cell cancers. Oral oncology 2016 Jan; 52.